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Abstract
Background: Disturbance in energy metabolism, as a key factor in diabetes-associated cognitive decline (DACD),
has become a promising therapeutic target of Chinese medicine ZiBu PiYin Recipe (ZBPYR). However, it is still not
clear how ZBPYR affects the mitochondrial function in DACD rats’ brains, which is considered as the crucial cell
organelle to supply energy for the brain.
Methods: Type 2 diabetes mellitus (T2DM) rat models were established by using high fat diet and streptozotocin
(STZ) (30 mg/kg, ip). The evaluation of insulin sensitivity was performed by oral glucose tolerance and insulin
tolerance test. After 7 weeks, the T2DM rats were treated with vehicle or ZBPYR for 11 weeks and morris water
maze (MWM) test were used to evaluate memory function. The ultra structural changes of prefrontal cortex (PFC)
and hippocampus were examined by transmission electron microscopy (TEM). The mitochondrial membrane
potential (ΔΨm) and reactive oxygen species (ROS) were measured with JC-1 and DCFDA assay. The levels of
insulin proteins were quantified by Western Blot analysis and the markers of histopathological changes were
detected by immunohistochemistry.
Results: ZBPYR could alleviate learning and memory impairment of DACD rats. TEM showed that ZBPYR prevented
mitochondrial ultra-structural alterations and number changes in the PFC and hippocampus of the DACD rats. In
addition, ZBPYR significantly increased ΔΨm and lowered the levels of ROS. Further investigation indicated that
ZBPYR suppressed the release of cytochrome c from mitochondria, strengthened insulin signaling and inhibited
GSK3β over-expression. These positive effects were associated with reduced Aβ1-42 deposition and restored
expression levels of microtubule-associated protein MAP2.
Conclusion: ZBPYR showed excellent protective effect against DACD via ameliorating mitochondrial dysfunction,
insulin resistance and histopathological changes.
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Background
Diabetes-associated cognitive decline (DACD) is diabetic
complication, due to changes in the central nervous sys-
tem (CNS) [1]. Considerable attention has been given to
DACD in the last decade [2]. Previous studies have
shown that cerebrovascular changes, oxidative stress, in-
creased expression of advanced glycation end products
(AGEs) and impaired cerebral insulin signaling are the
underlying causes of DACD [3–6]. Our recent data have
demonstrated that defection in energy metabolism of
hippocampus might affect the function of the brain. It
might be a key determinant of DACD [7].
Mitochondria are considered as crucial cell organelle
that produces energy for regulating the cellular metabol-
ism. It has been reported that brain mitochondria regu-
late energy-demanding neuro-transmission and calcium
homeostasis, which are important mechanisms for the
learning and memory process [8, 9]. In recent years, it
has become increasingly clear that there is correlation
between brain mitochondrial dysfunction and several
neurodegenerative diseases [10]. Mitochondrial dysfunc-
tion is an important contributor to the damage and loss
of neurons [11]. It has been also found that there was
significant decrease in neuron numbers in the cerebral
cortex or hippocampus in diabetic cognitive decline rats
[12, 13]. Therefore, preventing mitochondrial dysfunc-
tions is taken as a new therapeutic target for DACD.
Traditional Chinese medicine (TCM) has a long his-
tory in China. The ZiBu PiYin recipe (ZBPYR), derived
from a modification of the Zicheng Decoction, is a TCM
recorded in the book of Bujuji by Cheng Wu in the Qing
Dynasty [14]. Early reports demonstrated that ZBPYR
protected glutamate induced neuron injury and im-
proved learning and memory of pi-yin deficiency dia-
betic rats and type 2 diabetic rats [7, 14, 15]. Recent
findings have proved that ZBPYR could protect db/db
mice from reducing dendritic spine density, attenuated
brain leptin and insulin signaling pathway injury [16].
The potential effects of ZBPYR on the mitochondrial
function of the brain in DACD model have not been in-
vestigated yet. In the present work, we used high-fat diet
combined with Streptozotocin (STZ) rats as DACD
model, aiming to test the hypothesis that ZBPYR could
reverse the impairment of DACD mainly though alleviat-
ing brain mitochondrial dysfunction.
Methods
Tested drug and preparation
The ingredients of ZBPYR are: Red Ginseng, Common
Yam Rhizome, Indian Buead, White Peony Root, Dan shen
Root, White Hyacinth Bean, Lotus Seed, Grassleaf Sweet-
flag Rhizome, Thinleaf Milkwort Root, Sandalwood,
Tangerine Red Epicarp and Liquorice Root. All herbs were
purchased from Dalian Metro Pharmaceutical Co., Ltd.
(Dalian, Liaoning Province, China) and authenticated by
Prof. Yunpeng Diao (College of Pharmacy, Dalian Medical
University). Voucher Specimens were deposited at the au-
thors’ laboratory (Table 1). The herb mixtures (164.5 g)
were soaked in 8 volumes v/w of distilled water for
30 min and then boiled for 90 min [17]. The decoction
was then filtered through six-layer gauzes and made to a
concentration of 1 g crude drug/ml, and finally the decoc-
tion was transformed into the freeze-dried powder. A
91.2 g of the freeze-dried powder was extracted with
10 mL distilled water (9.12 g/mL) for 30 min under ultra-
sound and stored at 4 °C before use.
Experimental animals
Male Sprague–Dawley (SD) rats (Six week-old, 200 ± 20 g)
were purchased from the Experimental Animal Center of
Dalian Medical University (Dalian, China). They were
maintained at 22 ± 3 °C with 65 ± 5 % humidity on a 12 h
light/dark cycle during the experiments. All surgery was
performed under anesthesia with ether, and all efforts
were made to minimize suffering.
Experimental design
Thirty rats were randomly divided into three groups: cit-
rate buffer injected standard diet rats (Control group);
vehicle treated high-fat diet STZ rats (Model group);
ZBPYR treated high-fat diet STZ rats (ZBPYR group).
As shown in Fig. 1, high-fat diet (Anlimo Technology,
Nanjing, China) were started 4 weeks prior to the STZ
(Sigma, St Louis, MO, USA, 30 mg/kg, i.p) injection and
continued for 11 weeks. The suspension of STZ was
freshly dissolved in 0.1 M citrate buffer solution (Sigma,
St Louis, MO, USA). Body weight, food intake and water
intake of the rats were measured until 4 weeks high diet.
Glucose levels in tail blood samples were determined
using a glucometer (Accuchek; Roche, Mannheim,
Germany) after STZ for 3 days. The fasting serum insu-
lin (FSI), oral glucose tolerance test (OGTT) and insulin
tolerance test (ITT) were performed at 7, 12 and 16 days
after STZ injection. During a period of 7 weeks, ZBPYR
group rats were orally administered ZBPYR at a dose of
0.1 ml/10 g body weight, while the Control and Model
rats were orally administered an identical dose of ultra-
pure water (Milli-Q Integral Water Purification System,
Millipore Corporation, Billerica, MA, USA). At the end
of the experiment, body weight, food, water intake and
red blood glucose (RBG) of the rats were measured
among the three groups.
Morris water maze test
Spatial learning and memory performance was assessed
by morris water maze (MWM) test, which consisted of
5-day training (invisible plat training sessions and a
probe trial) and visible plat training session on day 6.
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The apparatus consisted of a circular pool (120 cm in
diameter, 50 cm in height and filled to a depth of 30 cm
with water maintained at 28 ± 1 °C) and a transparent
platform (9 cm in diameter and 29 cm in height), which
was hidden under water. An automatic photographic
was used to record the data (Institute of Materia Med-
ica, Chinese Academy of Medical Sciences, Beijing,
China). On the first day, rats were permitted to swim
freely in the tank for 60 s without the platform to adapt
to the new condition. Over the following 4 days, rats
were trained with four trials per day at intervals of 120 s
until they reached the platform and were allowed to rest
for 20 s. If the rat failed to reach the platform within
120 s, it was gently guided to the platform and stayed
for 20 s. The escape latency and swimming distance
taken to reach the platform were measured automatic-
ally. After hidden platform test, the platform was re-
moved. Rats had to swim for 120 s and the data
referring % of total time in target quadrant. Time in
searching original platforms and times across the plat-
form were recorded. On the 6th day, a visible-platform
test was undertaken. The platform was located 2 cm
over the water surface and placed at a position different
from the previous test. During this test, the escape la-
tency was recorded.
Ultrastructural examination by transmission electron
microscopy
4 % paraformaldehyde fixed prefrontal cortex (PFC) and
hippocampus samples (3 mm × 3 mm) of Control, Model
and ZBPYR groups were collected and fixed in 2 % glu-
taraldehyde in 0.1 mol/L sodium phosphate buffer
(pH 7.4) overnight at 4 °C. After dehydration with a
graded ethanol series, the sample was embedded in
Epon812 and sectioned using a Leica EM UC6 ultrami-
crotome (Leica Co., Vienna, Austria). Samples were
Table 1 The ingredients of Zibu Piyin Recipe
Chinese name Botanical Latin name Plant part used Weight (g) Voucher numbers
Hong-Shen Panax ginseng C.A.Mey. Red Ginseng Root 30 ZBPYR01-120920
Shan-Yao Dioscorea polystachya Turcz. Common Yam Rhizome 15 ZBPYR02-120920
Fu-Ling Wolfiporia extensa (Peck) Ginns Indian Buead 15 ZBPYR03-120920
Bai-Shao Paeonia lactiflora Pall. White Peony Root 15 ZBPYR04-120920
Dan-Shen Salvia miltiorrhiza Bunge Dan shen Root 12 ZBPYR05-120920
Bai-Bian-dou Lablab purpureus (L.) Sweet White Hyacinth Bean 15 ZBPYR06-120920
Lian-Zi Nelumbo nucifera Gaertn. Lotus Seed 20 ZBPYR07-120920
Shi-Chang-Pu Acorus gramineus Sol. ex Aiton Grassleaf Sweetflag Rhizome 10 ZBPYR08-120920
Yuan-Zhi Polygala tenuifolia Willd. Thinleaf Milkwort Root 10 ZBPYR09-120920
Tan-Xiang Santalum album L. Sandalwood 4.5 ZBPYR10-120920
Ju-Hong Citrus maxima ‘Tomentosa’ Tangerine Red Epicarp 9 ZBPYR11-120920
Gan-Cao Glycyrrhiza uralensis Fisch. ex DC. Liquorice Root 9 ZBPYR12-120920
Fig. 1 Design of the animal study. The control group was fed with standard diet during the whole study. The two diabetic groups received
high-fat diet until drug intervention (ZBPYR). In week 4 of the timeline, the two diabetic groups received STZ, while the control group was
administered vehicle citrate buffer. At 72 h, and 7, 12 and 16 days after STZ, RBG, FSI, OGTT and ITT were tested. From 7 weeks after the STZ
injection, ZBPYR was administered to the ZBPYR group daily for 7 weeks. The Control and Model groups received physiological saline. The Morris
water maze test was performed for 6 days before animals sacrificed
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viewed and photographed using Transmission Electron
Microscopy (TEM) (JEM-2000EX, JEDL, Japan).
Preparation mitochondria of prefrontal cortex and
hippocampus
The rats were sacrificed by an animal expert in accord-
ance with approved ministerial procedures appropriate
to the species. The PFC and hippocampus were quickly
separated and the tissue blocks were finely minced in
8 μm thickness [18]. 50 pieces of sections were collected
and homogenized in 1 mL isolation buffer according to
the Tissue Mitochondria Isolation Kit (MitoSciences,
Abcam, USA). The homogenate was centrifuged at
1000 g for 10 min at 4 °C and the supernatant was col-
lected and further centrifuged at 12,000 g for 15 min at
4 °C. Then, mitochondrial pellets were collected, resus-
pending in 1 mL isolation buffer supplemented with
10 μL protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO, USA) and further centrifuged at 12,000 g for
15 min at 4 °C. Finally, the mitochondrial pellets were
resuspended with 500 μL isolation buffer supplemented
with protease inhibitor. The concentration of mitochon-
drial protein was measured by the BCA protein assay kit
(cwbiotech, Beijing, China).
Mitochondrial membrane potential assay
Changes in mitochondrial membrane potential (ΔΨm)
were analyzed using a fluorescence spectrophotom-
eter (PARADIGM, Molecular Devices, USA) and a
mitochondria-selective dye (JC-1; Beyotime Institute of
Biotechnology, Bejing, China). JC-1 was a lipophilic cation,
driven by ΔΨm in normal polarized mitochondria as-
sembled into a red fluorescence-emitting dimer forming J-
aggregates. However, the monomeric form present in cells
with depolarized mitochondrial membranes emited only
green fluorescence.
Isolated mitochondria from PFC and hippocampus were
stained with JC-1 staining solution (5 μg/mL) for 15 min
at 37 °C and rinsed twice with assay buffer. The fluores-
cent intensity was analyzed on a spectrofluorometer as de-
scribed to detect green fluorescence at excitation/emission
wavelengths of 485/530 nm and red fluorescence at excita-
tion/emission wavelengths of 550/595 nm. The ratio of
red to green fluorescence intensity was determined for
each sample as a measure of ΔΨm.
Measurement of reactive oxygen species production
Reactive oxygen species (ROS) Assay Kit (Nanjing
Jiancheng Bioengineering Institute, Nanjing, China) was
used to quantify ROS levels of PFC and hippocampus tis-
sues to detect the changes of mitochondrial mass. The
fluorescent intensity of the tissue suspensions was mea-
sured by a fluorescence spectrophotometer (PARADIGM,
Molecular Devices, USA) at excitation wavelength of
485 nm and emission wavelength of 520 nm.
Protein extraction and western blotting analysis
The tissues of PFC and hippocampus were homogenized
in ice cold lysis buffer [7]. Then, the homogenate was
centrifuged at 15,000 g for 5 min at 4 °C prior to collect
the supernatants. Protein concentrations in the superna-
tants were measured using the bicinchoninic acid (BCA)
protein assay kit (cwbiotech, Beijing, China). 50 μg of
the sample proteins was separated by electrophoresis in
10 % sodium dodecylsulfate-polycrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylide-
nedi fluoride membrance (Amersham, Buckinghamshire,
UK). The membrance was blocked with 5 % skimmed
milk in TBS-T (10 mM Tris-Cl, PH 8.0, 150 mM NaCl
and 0.5 % Tween 20) at 4 °C overnight. It was rinsed
three times (10 min/time) with TBS-T, followed by 2 h
incubation with the first antibodies in the appropriate
concentrations and then 2 h incubation with HRP-
conjugated secondary antibody. The immuno-labeling
was detected using the enhanced chemiluminesence sys-
tem (Roche, GmbH, Mannheim, Germany) and visualized
using the UVP Bio-spectrum Imaging System (UVP, Inc,
Upland, CA, USA). Primary antibodies used from Cell Sig-
naling Technologies (Danvers, MA, USA) were: protein
kinase B (Akt) (#9272, 1:800), p-Ser473Akt (#4058, 1:800),
GSK3β (#9315, 1:800), p-Ser9GSK3β (#9322, 1:800) and
microtubule-associated protein 2 (MAP2) (#4542, 1:800).
Primary antibody directed against cytochrome c (Abcam,
Cambridge, UK, #ab110325, 1:800), insulin receptor sub-
strate 2 (IRS2) (Millipore Corporation, Billerica, MA,
USA, #MABS15, 1:2000) and p-Ser731 IRS-2 (Abcam
plc, Cambridge, UK, #ab3690, 1:200) were also used in the
experiments. Goat anti-rabbit (#NA9340, 1:2000) or
Goat anti-mouse (#NA9310, 1:2000) (GE Healthcare,
Buckinghamshire, UK) were used as secondary antibodies.
β-actin (Sigma-Aldrich, St Louis, MO, USA, #A2228,
1:2000) and Voltage-dependent anion channel (VDAC)
(Cell Signaling Technologies, Danvers, MA, USA, #4866,
1:800) were used as total internal quantitative control and
mitochondrial internal quantitative, respectively.
Immunohistochemistry staining for Aβ1-42 and MAP2
Rats from each group were deeply anesthetized with
pentobarbital sodium and perfused with 0.1 M PBS
followed by 4 % paraformaldehyde. Brains were removed
immediately and transferred to 15 %, 30 % sucrose solu-
tion (in PB) and then fixed in 4 % paraformaldehyde
overnight at 4 °C. Sections of PFC and hippocampus
were isolated and frozen on a cold stage, which was then
cut at 6 μm according to the routine procedure [19]. Im-
munohistochemical staining was performed using rabbit
anti-(Rat MAP2 IgG) at dilutions of 1:80 (Sigma-Aldrich,
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St Louis, MO, USA) and mouse anti-(Rat Aβ1-42 IgG) at
dilutions of 1:80 (Abcamplc, Cambridge, UK), respect-
ively. The sections without first antibody incubation
were used as background control. The images of PFC
and the CA1, CA3 and DG regions of the hippocampus
were captured by an upright microscope (Leica, Wetzlar,
Germany). The quantitative analysis was used by the
“integrated optical density” (IOD) function of Image
Pro-Plus version 6.0.
Statistical analysis
Statistical analysis was performed using either an
ANOVA (equal variance) or a Welch’s ANOVA (unequal
variance) test. Data from the MWM test was analyzed
using a repeated-measure analysis of variance for com-
parisons among trials. Student’s t test was used for com-
parison in two groups. The difference was considered to
be statistically significant when p < 0.05.
Results
Effects of ZBPYR on type 2 diabetes models
The results revealed that compared with the control
group, the body weight, food and water intake of model
rats were all increased rapidly due to the high-fat diet
administered prior to the STZ injection (Fig. 2a). How-
ever, the FSI of model group were changed but not obvi-
ously (p > 0.05, data not shown). After STZ, FSI in
model group was increased significantly (Fig. 2b). The
levels of blood glucose of OGTT were significantly
higher in model group than that of control group
(Fig. 2c-d). ITT results were showed insulin sensitivity
impaired in the model rats, but the group differences
were not significantly (Fig. 2e-f ). Following the injection
of STZ, water and food intake were slowly increased.
However, body weight in the model rats was decreased
compared with the control group. ZBPYR treatment
could make an obvious reduction in the food and water
intake and body weight (Fig. 2g). But it had no obvious
effects on blood glucose (Fig. 2h).
Effects of ZBPYR on diabetes-induced cognitive decline
In the hidden platform test, as shown in Fig. 3a, the es-
cape latency of the model group was longer than that of
the control group (days 2 to 4, p < 0.01; days 5, p < 0.05).
In contrast, ZBPYR group required a short escape la-
tency compared with model group (days 4, p < 0.01; days
5, p < 0.05). The swimming distance that the model rats
reached the platform was significantly increased com-
pared to the control group (days1, p < 0.05; days 2 to 4,
p < 0.01; days 5, p < 0.05). After ZBPYR treatment, we
found that the swimming distance was shorter than that
of model rats (days 4, p < 0.01; days 5, p < 0.05) (Fig. 3b).
In the probe trial, the percentage of the total time that
the model rats spent in the target quadrant was
significantly lower than control group (Fig. 3c, p < 0.01).
However, ZBPYR group performed differently compared
with model group (Fig. 3c, p < 0.05). Time in searching
original platform was also acquired by the probe trial
test. We found that the seconds that the model rats cost
during the test was not significantly different between
the control group and ZBPYR group (Fig. 3d). In
addition, the number of times that the model group rats
across the original platform was lower than that of con-
trol group (Fig. 3e, p < 0.05). However, there was no sig-
nificant difference between ZBPYR group and model
group. Performance in the visible platform version was
similar in the three groups in terms of escape latency
(Fig. 3f ). All these findings suggest that ZBPYR could at-
tenuate the impairment of learning and memory behav-
iors of the diabetic model rats.
Effects of ZBPYR on mitochondrial ultrastructure changes
Marked alterations in mitochondrial morphology and
the outcomes (×10,000) of PFC and hippocampus were
shown in Fig. 4a. Higher magnification (×40,000) showed
swelling of mitochondria associated with an increased
number of disordered and partially disrupted cristae in
the model group compared with the control group.
However, less damage of mitochondrial ultrastructures
in PFC and hippocampus was observed in the ZBPYR
group compared with the model group (Fig. 4b). Add-
itionally, in the model group, areas of both PFC and hip-
pocampal mitochondria were lower (59 % and 64 %,
respectively; p < 0.05) than that of the control group,
whereas higher (26 % and 13 %, respectively; p < 0.05) in
ZBPYR group than of model group (Fig. 4c and d).
Effects of ZBPYR on mitochondrial transmembrane
potential alterations
The levels of ΔΨm were shown in Fig. 5a. In the control
group, the ratio of JC-1 polymer/JC-1 monomer in PFC
and hippocampus were 1.65 ± 0.33 and 2.33 ± 0.28, respect-
ively. Compared with the control group, lower ratio in the
model group (PFC: 1.15 ± 0.26, p < 0.05 and hippocampus:
1.09 ± 0.42, p < 0.01, respectively) indicated the dissipation
of ΔΨm. ZBPYR group demonstrated the attenuated dissi-
pation of ΔΨm (PFC: 1.36 ± 0.12 and hippocampus: 1.88 ±
0.28, respectively; p < 0.05). The differences between the
ZBPYR group and the control group were only found in
hippocampus tissues.
Effects of ZBPYR on ROS Level
As shown in Fig. 5b, the increased ROS levels detected
by DCFH assay were observed in the PFC and hippo-
campus of model groups (p < 0.05), and ZBPYR signifi-
cantly inhibited the elevation of ROS levels with p < 0.01
in the PFC and p < 0.05 in the hippocampus.
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Effects of ZBPYR on neuron cytoskeleton proteins and
biomarker of inner mitochondrial membrane proteins
In the present work, the protein expression level of
neuron cytoskeleton protein MAP2 was measured. As
seen in Fig. 6a, MAP2 expression was obviously
increased by ZBPYR compared with model group in
PFC (p < 0.05). In addition, the activities of MAP2 were
also significantly increased by ZBPYR in hippocampus
(Fig. 5b, p < 0.05). Mitochondrial biomarker cytochrome
c was also investigated in this work. Compared with
Fig. 2 Diabetic rats was set up and treated by ZBPYR. a Body weight, food and water intake were measured after 4 weeks of high fat diet in
Control, Model and ZBPYR rats. b FSI levels were determined 7 days after STZ injection. c-d OGTT was performed 12 days after STZ. Blood
glucose levels were measured at the indicated times (c), and then the AUC was analyzed (d). e–f ITT was performed 16 days after STZ. Blood
glucose levels were measured at the indicated time (e), and then the AUC was analyzed (f). g Body weight, food and water intake were
measured after ZBPYR treatment in week 7. h RBG was detected after ZBPYR treatment in week 7. Mean ± S.E.M, n = 10. *Compared with Control
group; $ ZBPYR compared with Model group;*, $p < 0.05, **, $$p < 0.01
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model groups, the expression of cytochrome c in the
cytosol were down-regulated by ZBPYR with p < 0.05 in
PFC and hippocampus as shown in Fig. 6a and b, re-
spectively. However, level of cytochrome c in the mito-
chondria was enhanced in the PFC and hippocampus by
ZBPYR (Fig. 5c and d, p < 0.05), which indicated that the
release of cytochrome c from mitochondria was im-
proved after ZBPYR treatment.
Effects of ZBPYR on insulin signaling and GSK3β
In order to evaluate the effects of ZBPYR on insulin sig-
naling of DACD rats, the expressions of insulin signaling
factor IRS2 and p-Ser731 IRS2, Akt and p-Ser473 Akt in
PFC and hippocampus were evaluated by Western Blot
analysis. As shown in Fig. 7a and b, no obviously
changes of total levels of IRS2 or Akt before or after
ZBPYR treatment were checked in any brain region
Fig. 3 Effects of ZBPYR on DACD rats in morris water maze test. a Spatial memory acquisition phase, b swimming distance, c mean percentage
of total time in the target quadrant, d time in searching original platforms, e the number of times crossing the platform and f escape latency to
test visual acuity in Control, Model, and ZBPYR rats. Values are mean ± S.E.M, n = 10. *p < 0.05 and ** p < 0.01 vs. Control group; $ p < 0.05 and $$
p < 0.01 ZBPYR vs. Model group
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among the three groups. However, we observed a signifi-
cantly increased level of p-Ser731 IRS2 (p < 0.01) and ap-
parently down-regulation level of p-Ser473 Akt (p < 0.05)
in the PFC of model groups (Fig. 7a). In the same region
of ZBPYR group, the expression of p-Ser731 IRS2 was
markedly down-regulated (p < 0.01) and p-Ser473 Akt
was elevated compared with model group (p < 0.05).
Meanwhile, the proteins which were expressed in the
hippocampal groups were also tested (Fig. 7b). These
results indicated that compared with model groups,
expression of p-Ser731 IRS2 was significantly down-
regulated with p < 0.05 and p-Ser473 Akt was not chan-
ged apparently by ZBPYR (p < 0.01).
GSK3β was a well known down-stream target of insu-
lin signaling [20, 21] and we tested the expression of
GSK3β in our model. It was shown that there was no
change in the total level of GSK3β in PFC and hippo-
campus (Fig. 7a and b). However, a down-regulation of
p-GSK3β expression level at p-Ser9 was found in the
PFC and hippocampus of model groups (p < 0.05) and
ZBPYR increased the p-GSK3β level compared with the
model groups (p < 0.05).
Fig. 4 Alteration of mitochondria structure. TEM images at original magnifications of × 10,000 a and × 40,000 b in PFC and hippocampus
mitochondria of rats in control, model and ZBPYR groups. c and d Quantification of mitochondria in per section (analysis of 5 images in 3 rats
per group). Results were normalized by the mean value for control rats set to 1 unit. *Compared with Control group; $ ZBPYR compared with
Model group;*, $p < 0.05, **, $$p < 0.01
Fig. 5 Effect of ZBPYR on ΔΨm and ROS production in the PFC and hippocampus tissues of rats in control, model and ZBPYR groups. a Ratios of
JC-1 polymer to JC-1 monomer (red/green fluorescence). b The level of ROS production was monitored by the DCFH-DA assay. Data are
expressed as the mean ± SD. *p < 0.05 and **p < 0.01 compared with Control group. *Compared with Control group; $ ZBPYR compared with
Model group;*, $p < 0.05, **, $$p < 0.01
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Effects of ZBPYR on the expressions of Aβ1-42 and MAP2
In this work, the expression of Aβ1-42, which was the
characteristic of DACD, was detected [22]. The results
indicated that Aβ1-42 was observed almost negative in
the PFC, hippocampus CA1 and CA3 of control groups.
Additionally, the increased expression of Aβ1-42 was obvi-
ously detected in model groups in the different brain areas
(PFC: 16 times, CA1: 52 times and CA3: 60 times). In
addition, Aβ1-42 expression was significantly decreased by
ZBPYR with PFC: 0.37 times, CA1: 0.38 times and CA3:
Fig. 6 Effects of ZBPYR on cytochrome c (Cyto-C) and MAP2 levels. a and b ZBPYR significantly increased MAP2 expression and decreased Cyto-C
expression in cytosolic fractions in PFC and hippocampus, respectively. c and d ZBPYR significantly reduced the impairment of Cyto-C in PFC and
hippocampus, respectively. Representative Western Blot and bar graphs of gray-scale analysis were shown. β-action was used as a loading control
of cytosolic fractions. VDAC was used as a loading control of mitochondria. Data were presented as mean ± SD. *p < 0.05 and **p < 0.01 compared
with Control group. *Compared with Control group; $ ZBPYR compared with Model group;*, $p < 0.05, **, $$p < 0.01
Fig. 7 Effects of ZBPYR on insulin signaling and GSK3β activity. a and b ZBPYR reduced p-IRS2 at serine 731, increased p-Akt at serine 473 and
significantly improved GSK3β activity by increasing p-Ser9 GSK3β expression in the PFC and hippocampus, respectively. Data are presented as
mean ± SD. *Compared with Control group; $ ZBPYR compared with Model group;*, $p < 0.05, **, $$p < 0.01
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0.29 times compared with model groups (Fig. 8a and c).
There was no significant change in the hippocampal DG
(dentate gyrus) among the three groups (data not shown).
Furthermore, the biomarker of dendritic cytoskeleton
MAP2 was also investigated using immunohistochemistry
staining (Fig. 8b). The expression of MAP2 was signifi-
cantly decreased in the PFC (0.05 times), hippocampus
CA1 (0.1 times) and CA3 (0.06 times) of model groups
when compared with control groups. And we found the
expression of MAP2 was significantly increased after
ZBPYR treatment in these three areas (PFC: 14 timesl,
CA1:6 times, CA3: 10 times).
Discussion
DACD is considered as a common neurodegenerative
disease, which lacks an efficient therapeutic regimen
[23–25]. The high efficiency and low toxicity of TCM,
which has the advantage of providing multiple thera-
peutic effects on multiple targets, suggest the feasibility
in the treatment of DACD. TCM ZBPYR plays crucial
roles in learning and memory impairment in the diabetic
rats through inhibiting endoplasmic reticulum stress,
maintaining the morphology of dendritic spines and
ameliorating DACD in proteomic analysis [7, 14, 16].
The individual herbs used in ZBPYR exhibited some
pharmacological effects. For example, ginsenosides in
Panax ginseng C.A.Mey reduced cerebral ischemia-
induced tau phosphorylation and attenuated the symp-
toms of DACD [26, 27]. Additionally, senegenin from
Polygala tenuifolia Willd processed neuroprotective po-
tential against Aβ-induced neurotoxicity [28]. It was also
found that β-asarone in Acorus gramineus Sol. ex Aiton
had the therapeutic potential against high-fat diet in-
duced obesity in rats [29]. These compounds may con-
tribute to the effects of ZBPYR in preventing diabetes or
neuroprotection. In spite of that, the mechanism of
ZBPYR in regulating energy metabolism is still un-
known. Mitochondria play a central role in energy me-
tabolism. In the brain neurons, glucose is metabolized
by mitochondria to produce cellular energy. It has been
Fig. 8 Effects of ZBPYR on Aβ1-42 and MAP2. a Immunohistochemical staining (the main images, x50; inset boxes, x200) of Aβ1-42 in the PFC,
hippocampus CA1 and CA3. b Immunohistochemistry staining (the main images, x50; inset boxes, x200) of MAP2 in the PFC, hippocampus CA1
and CA3. c and d The average IOD of the immunoreactive area for Aβ1-42 and MAP2 was presented as bar graphs. Each bar represents mean ±
SD of three independent experiments (*Compared with Control group; $ ZBPYR compared with Model group;*, $p < 0.05, **, $$p < 0.01)
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reported that mitochondrial dysfunction existed in mul-
tiple peripheral tissues of diabetic rats [30–32]. However,
the mitochondrial functions in DACD animals were still
unclear. The aim of this study was to investigate the
function of brain mitochondria in high fat diet combined
with STZ induced DACD rats and its related mecha-
nisms of the protective effects of ZBPYR.
In our study, high fat diet combined with STZ injection
rat model showed hyperinsulinaemia and hyperglycaemia,
indicating that the diabetic model was successfully built.
In addition, the rat model registered cognitive decline by
MWM. ZBPYR treatment could restore the learning and
memory retrieval behaviors induced by diabetes.
The energy of brain mainly depends on mitochondria.
Maintaining mitochondrial function is essential for neuron
survival and offers protection against neurodegeneration
[33–36]. Here, we investigated the amount, structure, and
function of mitochondria in the DACD rat brain. Our data
indicated that the changes in mitochondrial density and
structure by TEM were observed in the region of PFC and
hippocampus of DACD rats. In addition, loss of ΔΨm and
increased production of ROS were also found in the model
groups, which suggested that mitochondria dysfunction
existed. ZBPYR could alleviate the changes in the structure
and increase the number of the mitochondria in per area.
It was also found that mitochondrial membrane potential
was pronounced and the level of ROS decreased in the
same region of brain after ZBPYR treatment. Taken to-
gether, these results proved that mitochondria dysfunction
was the mean target of ZBPYR. Accumulative evidence
suggests that alterations in mitochondrial structure and
function are associated with insulin signaling and related
complications [37–41]. Moreover, recent epidemiological
evidence suggests that CNS insulin resistance is a risk fac-
tor for cognitive decline [42–44]. Downstream targets of
insulin signaling pathway, e.g., insulin receptor substrate
serine phosphorylation 2 was up-regulated in the
brains of obese rats [45]. Akt, a key marker protein
of insulin signaling, mediates the effect of insulin via im-
portant intracellular signaling cascades including the
PI3K/Akt pathway [46, 47]. This work identified increase
in p-IRS2 and decrease in p-Akt in the PFC and hippo-
campus of model rats, suggesting that central insulin sig-
naling was impaired. ZBPYR could correct CNS insulin
resistance by regulating p-IRS2 and p-Akt. In addition,
ZBPYR exhibited strong activity in the inhibition of
GSK3β. GSK3β is a downstream substrate of Akt and is
the bridge connecting insulin signaling and Aβ, since the
phosphorylation states of GSK3β in the brain were found
to be involved in fluctuations of Aβ deposition [48–50]. In
this study, we found that GSK3β activity was inhibited
after ZBPYR treatment. Taken together, the present find-
ings provide molecular biological evidence for the pre-
ventive effects of ZBPYR on DACD.
Amyloid β was reported to be the predictor of demen-
tia and Aβ1-42 accumulation was found more obvious in
the brain of cognitive decline patients [51–53]. Our pre-
vious study indicated that Aβ1-42 was down-regulated in
db/db mice after ZBPYR treatment [16]. In the present
results, Aβ1-42 accumulation was more apparent in
model group in the region of PFC and hippocampus
(CA1 and CA3) and less detectable in ZBPYR group.
Then, the density of dendritic marker MAP2, which
reflected the changes of the neuronal morphology, was
significantly decreased in either brain region of the
models. ZBPYR was efficacious for alleviating the de-
creases in MAP2 levels, particularly in the PFC and
hippocampus (CA1 and CA3). We proposed that Aβ1-42
accumulation and low expression of MAP2 in brain were
the reason for DACD. ZBPYR significantly enhanced the
learning ability of the DACD rats, which is largely due
to the decrease in Aβ1-42 level and increase in MAP2
expression.
Conclusions
The findings of this study suggested that ZBPYR could
prevent the brain impairment of DACD rats. The related
mechanisms might be associated with improving mito-
chondrial dysfunction, insulin resistance and pathological
changes including expressions of Aβ and MAP2.
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